IBDEI3GX ; ; 19-NOV-2015
;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,58331,2)
;;=^5004465
;;^UTILITY(U,$J,358.3,58332,0)
;;=H35.32^^272^2906^28
;;^UTILITY(U,$J,358.3,58332,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58332,1,3,0)
;;=3^Exudative Age-Related Macular Degeneration
;;^UTILITY(U,$J,358.3,58332,1,4,0)
;;=4^H35.32
;;^UTILITY(U,$J,358.3,58332,2)
;;=^5005648
;;^UTILITY(U,$J,358.3,58333,0)
;;=H35.023^^272^2906^29
;;^UTILITY(U,$J,358.3,58333,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58333,1,3,0)
;;=3^Exudative Retinopathy,Bilateral
;;^UTILITY(U,$J,358.3,58333,1,4,0)
;;=4^H35.023
;;^UTILITY(U,$J,358.3,58333,2)
;;=^5005588
;;^UTILITY(U,$J,358.3,58334,0)
;;=H35.022^^272^2906^30
;;^UTILITY(U,$J,358.3,58334,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58334,1,3,0)
;;=3^Exudative Retinopathy,Left Eye
;;^UTILITY(U,$J,358.3,58334,1,4,0)
;;=4^H35.022
;;^UTILITY(U,$J,358.3,58334,2)
;;=^5005587
;;^UTILITY(U,$J,358.3,58335,0)
;;=H35.021^^272^2906^31
;;^UTILITY(U,$J,358.3,58335,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58335,1,3,0)
;;=3^Exudative Retinopathy,Right Eye
;;^UTILITY(U,$J,358.3,58335,1,4,0)
;;=4^H35.021
;;^UTILITY(U,$J,358.3,58335,2)
;;=^5005586
;;^UTILITY(U,$J,358.3,58336,0)
;;=H40.013^^272^2906^32
;;^UTILITY(U,$J,358.3,58336,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58336,1,3,0)
;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Bilateral
;;^UTILITY(U,$J,358.3,58336,1,4,0)
;;=4^H40.013
;;^UTILITY(U,$J,358.3,58336,2)
;;=^5005726
;;^UTILITY(U,$J,358.3,58337,0)
;;=H40.012^^272^2906^33
;;^UTILITY(U,$J,358.3,58337,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58337,1,3,0)
;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Left Eye
;;^UTILITY(U,$J,358.3,58337,1,4,0)
;;=4^H40.012
;;^UTILITY(U,$J,358.3,58337,2)
;;=^5005725
;;^UTILITY(U,$J,358.3,58338,0)
;;=H40.011^^272^2906^34
;;^UTILITY(U,$J,358.3,58338,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58338,1,3,0)
;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Right Eye
;;^UTILITY(U,$J,358.3,58338,1,4,0)
;;=4^H40.011
;;^UTILITY(U,$J,358.3,58338,2)
;;=^5005724
;;^UTILITY(U,$J,358.3,58339,0)
;;=H52.03^^272^2906^41
;;^UTILITY(U,$J,358.3,58339,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58339,1,3,0)
;;=3^Hypermetropia,Bilateral
;;^UTILITY(U,$J,358.3,58339,1,4,0)
;;=4^H52.03
;;^UTILITY(U,$J,358.3,58339,2)
;;=^5006262
;;^UTILITY(U,$J,358.3,58340,0)
;;=H52.02^^272^2906^42
;;^UTILITY(U,$J,358.3,58340,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58340,1,3,0)
;;=3^Hypermetropia,Left Eye
;;^UTILITY(U,$J,358.3,58340,1,4,0)
;;=4^H52.02
;;^UTILITY(U,$J,358.3,58340,2)
;;=^5006261
;;^UTILITY(U,$J,358.3,58341,0)
;;=H52.01^^272^2906^43
;;^UTILITY(U,$J,358.3,58341,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58341,1,3,0)
;;=3^Hypermetropia,Right Eye
;;^UTILITY(U,$J,358.3,58341,1,4,0)
;;=4^H52.01
;;^UTILITY(U,$J,358.3,58341,2)
;;=^5006260
;;^UTILITY(U,$J,358.3,58342,0)
;;=H59.41^^272^2906^44
;;^UTILITY(U,$J,358.3,58342,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58342,1,3,0)
;;=3^Inflammation of Postprocedural Bleb,Stage 1
;;^UTILITY(U,$J,358.3,58342,1,4,0)
;;=4^H59.41
;;^UTILITY(U,$J,358.3,58342,2)
;;=^5006426
;;^UTILITY(U,$J,358.3,58343,0)
;;=H59.42^^272^2906^45
;;^UTILITY(U,$J,358.3,58343,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58343,1,3,0)
;;=3^Inflammation of Postprocedural Bleb,Stage 2
;;^UTILITY(U,$J,358.3,58343,1,4,0)
;;=4^H59.42
;;^UTILITY(U,$J,358.3,58343,2)
;;=^5006427
;;^UTILITY(U,$J,358.3,58344,0)
;;=H59.43^^272^2906^46
;;^UTILITY(U,$J,358.3,58344,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3GX 3980 printed Dec 13, 2024@02:48:33 Page 2
IBDEI3GX ; ; 19-NOV-2015
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,99)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,58331,2)
+2 ;;=^5004465
+3 ;;^UTILITY(U,$J,358.3,58332,0)
+4 ;;=H35.32^^272^2906^28
+5 ;;^UTILITY(U,$J,358.3,58332,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,58332,1,3,0)
+8 ;;=3^Exudative Age-Related Macular Degeneration
+9 ;;^UTILITY(U,$J,358.3,58332,1,4,0)
+10 ;;=4^H35.32
+11 ;;^UTILITY(U,$J,358.3,58332,2)
+12 ;;=^5005648
+13 ;;^UTILITY(U,$J,358.3,58333,0)
+14 ;;=H35.023^^272^2906^29
+15 ;;^UTILITY(U,$J,358.3,58333,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,58333,1,3,0)
+18 ;;=3^Exudative Retinopathy,Bilateral
+19 ;;^UTILITY(U,$J,358.3,58333,1,4,0)
+20 ;;=4^H35.023
+21 ;;^UTILITY(U,$J,358.3,58333,2)
+22 ;;=^5005588
+23 ;;^UTILITY(U,$J,358.3,58334,0)
+24 ;;=H35.022^^272^2906^30
+25 ;;^UTILITY(U,$J,358.3,58334,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,58334,1,3,0)
+28 ;;=3^Exudative Retinopathy,Left Eye
+29 ;;^UTILITY(U,$J,358.3,58334,1,4,0)
+30 ;;=4^H35.022
+31 ;;^UTILITY(U,$J,358.3,58334,2)
+32 ;;=^5005587
+33 ;;^UTILITY(U,$J,358.3,58335,0)
+34 ;;=H35.021^^272^2906^31
+35 ;;^UTILITY(U,$J,358.3,58335,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,58335,1,3,0)
+38 ;;=3^Exudative Retinopathy,Right Eye
+39 ;;^UTILITY(U,$J,358.3,58335,1,4,0)
+40 ;;=4^H35.021
+41 ;;^UTILITY(U,$J,358.3,58335,2)
+42 ;;=^5005586
+43 ;;^UTILITY(U,$J,358.3,58336,0)
+44 ;;=H40.013^^272^2906^32
+45 ;;^UTILITY(U,$J,358.3,58336,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,58336,1,3,0)
+48 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Bilateral
+49 ;;^UTILITY(U,$J,358.3,58336,1,4,0)
+50 ;;=4^H40.013
+51 ;;^UTILITY(U,$J,358.3,58336,2)
+52 ;;=^5005726
+53 ;;^UTILITY(U,$J,358.3,58337,0)
+54 ;;=H40.012^^272^2906^33
+55 ;;^UTILITY(U,$J,358.3,58337,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,58337,1,3,0)
+58 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Left Eye
+59 ;;^UTILITY(U,$J,358.3,58337,1,4,0)
+60 ;;=4^H40.012
+61 ;;^UTILITY(U,$J,358.3,58337,2)
+62 ;;=^5005725
+63 ;;^UTILITY(U,$J,358.3,58338,0)
+64 ;;=H40.011^^272^2906^34
+65 ;;^UTILITY(U,$J,358.3,58338,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,58338,1,3,0)
+68 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Right Eye
+69 ;;^UTILITY(U,$J,358.3,58338,1,4,0)
+70 ;;=4^H40.011
+71 ;;^UTILITY(U,$J,358.3,58338,2)
+72 ;;=^5005724
+73 ;;^UTILITY(U,$J,358.3,58339,0)
+74 ;;=H52.03^^272^2906^41
+75 ;;^UTILITY(U,$J,358.3,58339,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,58339,1,3,0)
+78 ;;=3^Hypermetropia,Bilateral
+79 ;;^UTILITY(U,$J,358.3,58339,1,4,0)
+80 ;;=4^H52.03
+81 ;;^UTILITY(U,$J,358.3,58339,2)
+82 ;;=^5006262
+83 ;;^UTILITY(U,$J,358.3,58340,0)
+84 ;;=H52.02^^272^2906^42
+85 ;;^UTILITY(U,$J,358.3,58340,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,58340,1,3,0)
+88 ;;=3^Hypermetropia,Left Eye
+89 ;;^UTILITY(U,$J,358.3,58340,1,4,0)
+90 ;;=4^H52.02
+91 ;;^UTILITY(U,$J,358.3,58340,2)
+92 ;;=^5006261
+93 ;;^UTILITY(U,$J,358.3,58341,0)
+94 ;;=H52.01^^272^2906^43
+95 ;;^UTILITY(U,$J,358.3,58341,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,58341,1,3,0)
+98 ;;=3^Hypermetropia,Right Eye
+99 ;;^UTILITY(U,$J,358.3,58341,1,4,0)
+100 ;;=4^H52.01
+101 ;;^UTILITY(U,$J,358.3,58341,2)
+102 ;;=^5006260
+103 ;;^UTILITY(U,$J,358.3,58342,0)
+104 ;;=H59.41^^272^2906^44
+105 ;;^UTILITY(U,$J,358.3,58342,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,58342,1,3,0)
+108 ;;=3^Inflammation of Postprocedural Bleb,Stage 1
+109 ;;^UTILITY(U,$J,358.3,58342,1,4,0)
+110 ;;=4^H59.41
+111 ;;^UTILITY(U,$J,358.3,58342,2)
+112 ;;=^5006426
+113 ;;^UTILITY(U,$J,358.3,58343,0)
+114 ;;=H59.42^^272^2906^45
+115 ;;^UTILITY(U,$J,358.3,58343,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,58343,1,3,0)
+118 ;;=3^Inflammation of Postprocedural Bleb,Stage 2
+119 ;;^UTILITY(U,$J,358.3,58343,1,4,0)
+120 ;;=4^H59.42
+121 ;;^UTILITY(U,$J,358.3,58343,2)
+122 ;;=^5006427
+123 ;;^UTILITY(U,$J,358.3,58344,0)
+124 ;;=H59.43^^272^2906^46
+125 ;;^UTILITY(U,$J,358.3,58344,1,0)
+126 ;;=^358.31IA^4^2
